lenalidomide (REVLIMID°) in untreated multiple myeloma.
出版信息
Prescrire Int. 2016 Nov;25(176):263-264.
PMID:30715822
Abstract
In an unblended trial in 1623 multiple myeloma patients, treatment with lenalidomide + dexamethasone until disease progression appeared to prolong survival by a few months more than with the thalidomide + melphalan + prednisone combination given for 18 months, but serious adverse effects were more frequent.
摘要
Zotero 插件